RECEIVED
CENTRAL FAX CENTER

SEP 2 2 2006

REMARKS

Claims 2-25, 46, 51, 52, 55-57 and 59 are currently pending. Claims 46, 56 and 59 have been amended. Claims 44, 45, 53, 54, 58, 60 and 61 have been canceled without prejudice. Applicants reserve the right to prosecute any canceled subject matter in one or more divisional, continuation or continuation-in-part applications. No new matter has been added.

Response to Restriction Requirement

The Examiner has restricted the invention under 35 U.S.C. §121 to five inventions as follows:

Group I: Claims 58-61, directed to compositions comprising a combination of compound 287 and loratedine or desloratedine, and methods of using the compositions to treat allergy;

Group II: Claims 46, 51, 52 and 55, directed to compositions comprising a combination of a compound of claim 51 other than compound 287 and loratedine or desloratedine, and methods of using the compositions to treat allergy;

Group III: Claims 45, 51, 52 and 54, directed to compositions comprising a combination of a compound of claim 51 and fexofenadine or cetirizine, and methods of using the compositions to treat allergy;

Group IV: Claims 44, 51, 52 and 53, directed to compositions comprising a combination of a compound other than compound 287 and an H1 receptor antagonist, and methods of using the compositions to treat allergy; and

Group V: Claims 2-25, 56 and 57, directed to compositions comprising a combination of a compound of formula (I) and an H1 receptor antagonist, and methods of using the compositions to treat allergy.

If electing from among Groups II-V, the Examiner additionally required the election of a single species from claim 51 for prosecution on the merits.

If electing from Groups I-IV, claims 2-25, 56 and 57 can be prosecuted with the group to the extent of the elected compound and and the other therapeutic agent(s).

Applicants elect, without traverse, the claims of Group II, claims 2-25, 46, 51, 52 and 55-57 directed in part to compositions comprising a combination of a

compound of claim 51 other than compound 287 and loratadine or desloratadine, and methods of using the compositions to treat allergy. Applicants further elect the following species of claim 51:

If the undersigned can be of any assistance to the Examiner in addressing issues to advance the application to allowance, please contact the undersigned at the number set forth below.

September 22, 2006 Schering-Plough Corporation 2000 Galloping Hill Road Patent Department, K-6-1,1990 Kenilworth, NJ 07033

Tel: (908) 298-7475 Fax: (908) 298-5388 Respectfully submitted,

Attorney for Applicants
Reg No. 31.463